<DOC>
	<DOCNO>NCT00086801</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , vinblastine , gemcitabine , work different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : This phase II trial study well combination chemotherapy work treat patient newly diagnose stage I stage II Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Newly Diagnosed Stage I Stage II Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response rate patient newly diagnose stage IA , IB , IIA , IIB non-bulky Hodgkin 's lymphoma treat doxorubicin , vinblastine , gemcitabine . Secondary - Determine event-free survival patient treat regimen . - Determine toxicity regimen patient . - Determine whether fludeoxyglucose F 18 positron-emission tomography scan useful predict clinical relapse determine presence residual disease patient treatment regimen . OUTLINE : This multicenter study . Patients receive doxorubicin IV 3-5 minute , vinblastine IV 3-5 minute , gemcitabine IV 30 minute day 1 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients undergo fludeoxyglucose F 18 positron-emission tomography ( PET ) scan CT scan treatment course 2 6 therapy ass response . Patients positive PET scan completion study therapy may undergo biopsy . A PET scan perform 3 month later biopsy negative biopsy unable perform . Patients follow every 3 month 1 year , every 4 month 2 year , every 6 month 2 year , annually 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>1 . Documentation Disease : 1.1 Histologically document Hodgkin lymphoma subclassified accord WHO modification Rye Classification stag accord modify Ann Arbor Staging Classification system . Patients must clinical stage IA , IB , IIA IIB . Patients `` E '' extension eligible criterion meet . Nodular lymphocyte predominant Hodgkin lymphoma exclude . Core biopsy acceptable contain adequate tissue primary diagnosis immunophenotyping . Fine needle aspirate ( FNA ) cytologies bone marrow biopsy sole mean diagnosis acceptable . Note : Failure submit pathology slide within 60 day patient registration result patient declare ineligible . 1.2 Patients may mediastinal mass &gt; 0.33 maximum intrathoracic diameter stand posteroanterior chest xray peripheral retroperitoneal adenopathy &gt; 10 cm large diameter . 1.3 Bone marrow biopsy require pretreatment evaluation . Bilateral biopsy prefer require . 2 . No prior treatment ( chemotherapy radiation therapy ) Hodgkin lymphoma . 3 . Measurable disease must present either physical examination image study . Any tumor mass measurable two dimension &gt; 2 cm acceptable ( 1.5 cm 0.5 cm slice use spiral CT scan ) . Lesions consider intrinsically nonmeasurable include follow : bone lesion leptomeningeal disease ascites pleural/pericardial effusion inflammatory breast disease lymphangitis cutis/pulmonis abdominal mass confirm followed imaging technique cystic lesion lesion situate previously irradiate area 4 . Age ≥ 16 year 5 . Performance status 02 6 . LVEF ECHO MUGA within institutional normal limit 7 . DLCO ≥ 60 % symptomatic pulmonary disease 8 . No known HIV infection . Patients history intravenous drug abuse behavior associate increase risk HIV infection test exposure HIV virus . Patients test positive know infected eligible due increase risk infection chemotherapy regimen . An HIV test require entry protocol , require patient perceive risk . 9 . Nonpregnant nonlactating . Due teratogenic potential agent use study , pregnant nursing woman may enrol . Women men reproductive potential agree use effective mean birth control . 10 . Initial Required Laboratory Data : ANC ≥ 1000/μL Platelet count ≥ 100,000/μL Serum Creatinine ≤ 2 mg/dL Bilirubin ≤ 2 mg/dL AST ≤ 2 x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
</DOC>